Michael Elliot Shankman
CIK: 0002035175
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LEXX
Lexaria Bioscience Corp.
Officer
Discretionary Trading P&L
Holdings
About Shankman Michael Elliot
Shankman Michael Elliot (SEC CIK 0002035175) files insider reports with the SEC as Chief Financial Officer of Lexaria Bioscience Corp. (LEXX).
Signal8 holds 2 ownership filings by Shankman Michael Elliot (1 Form 3, 1 Form 4), filed between Oct 2, 2024 and May 16, 2025. Those filings report 1 transaction, the latest on May 15, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Shankman Michael Elliot's filings is in DANVILLE, CA.
Recent filings by Shankman Michael Elliot
- May 15, 2025: Grant or award of LEXX derivative securities (Form 4, code A).
Other insiders filing for Lexaria Bioscience Corp. (LEXX)
- BUNKA CHRISTOPHER, Director
- DOCHERTY JOHN MARTIN, President
- Carle Vanessa, Secretary
- CHRISTOPHER RICHARD, Chief Executive Officer
- Bhullar Baljinder, Director
- Baxter Nicholas W, Director